<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lecture 6: General Anesthesia</title>
    <link rel="stylesheet" href="styles.css">
</head>
<body>
    <header>
        <h1>Lecture 6: General Anesthesia</h1>
        <nav>
            <ul>
                <li><a href="index.html">Home</a></li>
                <li><a href="lecture1.html">Lecture 1</a></li>
                <li><a href="lecture2.html">Lecture 2</a></li>
                <li><a href="lecture3.html">Lecture 3</a></li>
                <li><a href="lecture4.html">Lecture 4</a></li>
                <li><a href="lecture5.html">Lecture 5</a></li>
                <li><a href="lecture6.html">Lecture 6</a></li>
            </ul>
        </nav>
    </header>

    <section id="lecture6">
        <h2>Key Concepts</h2>
                    <ol>
                <li><strong>Meyer-Overton Correlation:</strong> This theory links anesthetic potency to lipid solubility. However, its limitations became apparent with the discovery of specific ion channel interactions.</li>
                <li><strong>Anesthetic Targets:</strong> General anesthetics enhance GABAergic inhibition (GABA-A receptors) and suppress excitatory neurotransmission (NMDA receptors).</li>
                <li><strong>MAC (Minimum Alveolar Concentration):</strong> MAC is a measure of anesthetic potency, representing the concentration needed to prevent movement in 50% of subjects during surgery.</li>
                <li><strong>Two-Pore Domain K‚Å∫ Channels:</strong> These channels contribute to the hyperpolarizing effects of certain anesthetics, stabilizing neuronal membranes.</li>
                <li><strong>Fetal Alcohol Syndrome (FAS):</strong> Neurotoxic effects of alcohol exposure parallel those of anesthetics, impacting GABAergic and NMDA receptor function during development.</li>
                <li><strong>Neuroprotection vs. Neurotoxicity:</strong> While anesthetics protect against excitotoxicity, prolonged exposure in developing brains can cause neurodegeneration.</li>
                <li><strong>Stages of Anesthesia:</strong> Includes induction, maintenance, and emergence phases, each requiring specific pharmacological strategies.</li>
                <li><strong>Anesthetic Synergy:</strong> Combining agents (e.g., propofol and opioids) reduces the required dose of each, minimizing side effects.</li>
                <li><strong>Adverse Effects:</strong> Common issues include respiratory depression, hypotension, and post-operative cognitive dysfunction (POCD).</li>
                <li><strong>Future Directions:</strong> Research focuses on developing agents with faster recovery profiles and fewer side effects.</li>
            </ol>
            <table>
                <thead>
                    <tr>
                        <th>Anesthetic</th>
                        <th>Primary Target</th>
                        <th>Effects</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Propofol</td>
                        <td>GABA-A Receptors</td>
                        <td>Rapid induction, sedation, and amnesia</td>
                    </tr>
                    <tr>
                        <td>Ketamine</td>
                        <td>NMDA Receptors</td>
                        <td>Dissociative anesthesia and analgesia</td>
                    </tr>
                </tbody>
            </table>
    </section>

    <footer>
        <p>&copy; 2023 Neuropharm Review</p>
    </footer>
</body>
</html>